


# PRODUCT INFORMATION



## BX 471

Item No. 18503

**CAS Registry No.:** 217645-70-0  
**Formal Name:** N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]-urea  
**MF:** C<sub>21</sub>H<sub>24</sub>ClFN<sub>4</sub>O<sub>3</sub>  
**FW:** 434.9  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 211, 244, 288 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

BX 471 is supplied as a crystalline solid. A stock solution may be made by dissolving the BX 471 in the solvent of choice, which should be purged with an inert gas. BX 471 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of BX 471 in these solvents is approximately 14, 25, and 30 mg/ml, respectively.

BX 471 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BX 471 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BX 471 has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

The CC chemokine receptor-1 (CCR1), whose ligands include macrophage inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ), RANTES, and monocyte chemoattractant protein-3 (MCP-3), has a central role in leukocyte trafficking and is highly expressed in certain autoimmune diseases. BX 471 is a nonpeptide CCR1 antagonist that has been shown to displace MIP-1 $\alpha$ , RANTES, and MCP-3 with K<sub>i</sub> values of 1, 2.8, and 5.5 nM, respectively.<sup>1</sup> It demonstrates >10,000-fold selectivity for CCR1 over 28 additional G protein-coupled receptors, including related chemokine receptors.<sup>1</sup> In a rat experimental allergic encephalomyelitis model of multiple sclerosis, BX 471 at 50 mg/kg was shown to significantly reduce the severity of the disease.<sup>1</sup> BX 471 also decreases the inflammatory response during sepsis, blocks migration of monocytes isolated from rheumatoid arthritis patients, and prevents macrophage and T cell recruitment in a mouse model of lupus nephritis.<sup>2-4</sup>

### References

1. Liang, M., Mallari, C., Rosser, M., *et al.* *J. Biol. Chem.* **275**(25), 19000-19008 (2000).
2. He, M., Horuk, R., Moochhala, S., *et al.* *Am. J. Physiol. Gastrointest. Liver Physiol.* **292**(4), G1173-G1180 (2007).
3. Lebre, M.C., Vergunst, C.E., Choi, I.Y.K., *et al.* *PLoS One* **6**(7), (2011).
4. Anders, H.-J., Belemzova, E., Eis, V., *et al.* *J. Am. Soc. Nephrol.* **15**(6), 1504-1513 (2004).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM